Valion Bio
VBIO
7 hedge funds and large institutions have $119K invested in Valion Bio in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
7.83% less ownership
Funds ownership: 12.46% → 4.64% (-7.8%)
79% less capital invested
Capital invested by funds: $567K → $119K (-$448K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$43K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.4K |
| 3 |
Citigroup
New York
|
+$8.16K |
| 4 |
MG
Marex Group
London,
|
+$5.82K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$156K |
VBIO Hedge Fund Activity: Q4 2025 in Review
7 of the 8,276 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q4 2025, worth a combined $119K — down 79% from $567K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new VBIO positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $43K. The largest seller was DRW Securities, exiting entirely with an estimated $156K sold.
- 7 institutional investors held Valion Bio (VBIO) as of Q4 2025, up from 6 in Q3 2025.
- Funds reported $119K of Valion Bio stock for Q4 2025, down 79% quarter-over-quarter.
- 3 funds opened new Valion Bio positions in Q4 2025 and 1 closed out, a net change of +2 holders.
- The largest Valion Bio buyer in Q4 2025 was UBS Group, an estimated $43K added.
- The largest Valion Bio seller in Q4 2025 was DRW Securities, an estimated $156K sold.
Based on aggregated 13F filings for Q4 2025.